SAN JOSE, Calif.–(BUSINESS WIRE)–NetApp® (NASDAQ: NTAP), l’azienda specializzata in infrastrutture intelligenti per i dati, oggi ha annunciato l’intenzione di rilevare PEAK:AIO, un pioniere nell’architettura dei metadati di nuova generazione e nei sistemi di file paralleli ad alte prestazioni. L’acquisizione prevista punta ad accelerare il programma di infrastrutture AI di NetApp aumentando i servizi di metadati e l’innovazione parallela dei namespace progettati per aiutare i cloud dell’AI ad
Month: September 2026
PASCAGOULA, Miss.–(BUSINESS WIRE)–Merchants & Marine Bancorp, Inc. (OTCQX: MNMB) (the “Company”) today announced that its wholly owned bank subsidiary, Merchants & Marine Bank, will change its legal name to TownBridge Bank, effective September 28, 2026. The name change does not reflect a sale, merger, acquisition, or change in ownership or leadership. Instead, TownBridge Bank establishes a shared bank charter identity for the Company’s growing Family of Brands while allowing its commu
SAN JOSÉ, Californie–(BUSINESS WIRE)–NetApp® (NASDAQ : NTAP), l’entreprise d’infrastructure de données intelligente, annonce aujourd’hui son intention d’acquérir PEAK:AIO, pionnier de l’architecture de métadonnées de nouvelle génération et des systèmes de fichiers parallèles haute performance. L’acquisition envisagée vise à accélérer la feuille de route de NetApp en matière d’infrastructure d’IA, en enrichissant ses services de métadonnées et son innovation en matière d’espaces de noms parall
SEATTLE–(BUSINESS WIRE)– #airo–As Amtrak prepares to debut it’s new $8 billion Airo trainsets – SeaPort Airlines is offering an alternative that cuts the travel time by over half and requires no massive public investment of funds. “I love the train. But not if I have to get somewhere. Or by a certain time,” says SeaPort Airlines Founder and CEO Kent Craford. “SeaPort Airlines was founded to get the Pacific Northwest moving again, shortening the distance between our major cities, so you can leave hom
AURORA, Colo.–(BUSINESS WIRE)– #biotech–RefinedScience today announced a multi-institutional agreement that puts the Marsico Pancreatic Cancer Initiative on track to become the world’s largest multimodal single-cell pancreatic ductal adenocarcinoma (PDAC) dataset by the end of 2026, with contracted and partnered access to more than 2,000 consented pancreatic cancer samples from leading academic and industry sources. Pancreatic cancer is among the deadliest major cancers, in large part because the disea
VERNON HILLS, Ill.–(BUSINESS WIRE)–CDW (Nasdaq: CDW), the strategic end-to-end technology partner that turns customer ambition into outcomes, today announced that it has completed its previously announced acquisition of Lovelytics, a leading data and AI services firm and a member of the Databricks Brickbuilder Partner Network. The acquisition expands CDW’s Services & Solutions portfolio and will bring the Lovelytics capabilities to a broader set of customers. Lovelytics helps organization
GRAPEVINE, Texas–(BUSINESS WIRE)–On September 23, 2026, Southland Holdings, Inc. (NYSE American: SLND and SLND WS) (the “Company”) received notification (the “Notice”) from NYSE Regulation of the NYSE American LLC (“NYSE American”) that the Company is no longer in compliance with NYSE American’s continued listing standards. Specifically, the Notice states that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(i) and 1003(a)(ii) of the NYSE Ame
User Survey Demonstrates High Satisfaction of the LIBERTY System
Expansion of Sales Footprint Expands to Western U.S. as Company Secures First California Customer
HINGHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), announced that it highlighted the continuation of its commercial and growth strategy during an analyst meeting held in New York City on Thursday, September 24, 2026. The Company also highlighted select results from a user survey, available on the Company’s website, conveying high satisfaction with the system.
Key Topics Discussed:
- Expansion of the U.S. footprint is continuing, and the Company is on track to have 12 sales territories by the end of the year, to accelerate growth and support the Company’s first customer in California and its expansion in North Carolina.
- The Company’s commercial strategy has evolved to engage Value Analysis Committee (VAC) process earlier, a four-to-six-month process based on the Company’s current experience, to gain widespread access to hospital systems. The Company believes this approach will accelerate adoption of the LIBERTY System across healthcare systems with multiple hospitals. The Company is now engaged with the VAC at multiple health systems.
- Hired three additional Area Sales Managers and an additional Regional Sales Director to focus on new sales territories and expand west.
- The Company continues to advance and focus on operating efficiencies, such as adding a second manufacturing line and moving to more efficient manufacturing processes, which the Company expects will result in positive gross margins in 2027.
- Potential expansions to certain international markets, including in Asia and the Middle East, where the Company can leverage its FDA clearance, are in advanced stages, while the Company continues its engagement with regulatory bodies to support future CE mark approval which is expected in late Q4 2026 or early Q1 2027.
LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
NORWALK, Conn.–(BUSINESS WIRE)–Silgan to Release Third Quarter 2026 Earnings Results on October 29, 2026
MIAMI–(BUSINESS WIRE)–On September 25, 2026, the Fairholme Focused Income Fund (“FOCIX” or the “Fund”) distributed an Ordinary Income dividend of $0.05297 per share to shareholders of record as of September 24, 2026. The Fund’s Net Asset Value (“NAV”) was reduced by the amount of the distribution. The Record Date, Ex-Dividend Date, Payable Date, and Cents-Per-Share are as follows: THE FAIRHOLME FOCUSED INCOME FUND Distribution Type Record Date Ex-Dividend Date Payable Date Cents-Per-Share Ord